Clinical Trial Update: Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating intrathecal azacitidine in combination with nivolumab for recurrent high-grade glioma. The study is currently enrolling…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-mutant Who
• Diffuse Hemispheric Glioma H3 G34-mutant
• Diffuse Midline Glioma
• Glioblastoma
• Gliosarcoma of Brain

Drugs mentioned

• Azacitidine (intrathecal) (azacitidine)
• nivolumab (nivolumab)

Snippet

Sponsor: Andrew P. Groves | Conditions: Glioblastoma (GBM), Diffuse Midline Glioma (DMG) | Phase 1 | Status: ENROLLING_BY_INVITATION